EnovisENOV +1.09%61 EBITDA Margin % is 14.11% as of Mar. 2026, which is 19% above its 10-year median of 11.84. GuruFocus rates ENOV with a GF Score™ of 61/100 and a GF Value™ of $49.60 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Enovis ranks worse than 75.12% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Enovis's EBITDA for the
three
months ended in Mar. 2026 was $83 Mil. Enovis's Revenue for the
three
months ended in Mar. 2026 was $589 Mil. Therefore, Enovis's EBITDA margin for the quarter that ended in Mar. 2026 was 14.11%.
Enovis (NYSE:ENOV) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Enovis EBITDA Margin % Related Terms
Enovis EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Enovis's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ENOV vs IART, AHCO, ALMR: EBITDA Margin % Comparison
For the Medical Devices subindustry, Enovis's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enovis EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Enovis's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Enovis's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enovis (ENOV) has a EBITDA Margin % of 14.11% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Enovis and its competitors. This is 19% above median its historical median of 11.84. According to the industry distribution chart, Enovis ranks #613 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 75.1%.
Is Enovis' EBITDA Margin % too high?
Enovis' current EBITDA Margin % of 14.11% is 19% above median its 10-year median of 11.84. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Enovis' value of 14.11% is 88.8% above this industry median. Based on the distribution chart, Enovis ranks #613 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Enovis has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Enovis' EBITDA Margin % compare to IART and AHCO?
According to the Medical Devices & Instruments industry distribution chart, Enovis ranks #613 out of 816 companies for EBITDA Margin %. This places Enovis in the lower half of its industry. The industry median EBITDA Margin % is 7.48. Enovis' value of 14.11% is 88.8% above this benchmark. While the company's 10-year median is 11.84 vs. the industry median of 7.48, Enovis has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Enovis's current EBITDA Margin % of 14.11% is 88.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Enovis and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enovis's current EBITDA Margin % is 14.11%, which is 19% above median its own 10-year median of 11.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enovis stock overvalued right now?
Based on GuruFocus' analysis, Enovis (ENOV) is currently considered Possible Value Trap. The stock's GF Value™ is $49.60, compared to a current price of $21.38 — trading 56.9% below its estimated fair value. The current EBITDA Margin % is 14.11%, which is 19% above median its 10-year median of 11.84 and 88.8% above the Medical Devices & Instruments industry median of 7.48. Enovis' overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Enovis (ENOV), the current EBITDA Margin % is 14.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Enovis (ENOV) Overvalued in 2026?
Based on GuruFocus' analysis, Enovis stock appears to be undervalued.
The current stock price of $21.38 is trading 56.9% below its estimated GF Value™ of $49.60.
GuruFocus considers Enovis to be Possible Value Trap.
Key valuation signals for ENOV:
EBITDA Margin %: 14.11% (19% above median its 10-year median of 11.84)
GF Value™: $49.60 vs. price of $21.38 (56.9% below fair value)
Industry Position: 88.8% above the Medical Devices & Instruments median (#613 of 816)
No single metric tells the full story. See the ENOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.
61GF Score
Get the complete analysis for ENOV
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ENOV has been successfully added to your 
